Tumor Biology Center Freiburg, Germany
Angiogenesis and tumorigenesis in follistatin and activin expressing tumors are not interconnected
Published in Medicine and Law Weekly, August 4th, 2006
According to recent research published in the journal Cancer Research, "The transforming growth factor-beta superfamily member activin and its antagonist, follistatin, act as a pleiotropic growth factor system that controls cell proliferation, differentiation, and apoptosis. Activin inhibits fibroblast growth factor 2-induced sprouting angiogenesis in vitro (spheroidal angiogenesis assay) and in vivo (Matrigel assay)."
"To further study the role of the activin/follistatin system during angiogenesis and tumor progression, activin- and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
More Articles from Medicine and Law Weekly
- Acrux
Acrux appoints business development directors - Advanced Medical Optics
Advanced Medical Optics announces settlement with Alcon of patent infringement suits - American Legacy Foundation, U.S.
Florida Supreme Court decision leaves little or no redress against U.S. tobacco companies - CAS Medical Systems
CAS Medical awarded two U.S. patents for Cerebral Oximeter Technology - China Biopharmaceuticals
China Biopharmaceuticals completes acquisition of Enshi Pharmaceuticals - Diabetes Prevention
Diabetes Prevention Program cost sharing may give financial returns in long-term - More from this issue of Medicine and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
